Regeneron has once again received a complete response letter (CRL) from the US Food and Drug Administration (FDA) for the ...

Regeneron investors should embrace the fact that Eylea is no longer a growth product and focus on the rest of the commercial ...

The bear phase in Regeneron (REGN) appears over. Shares bottomed at around $550 - $575 and jumped by around 12% to over $650 ...

Despite the rejection, analysts saw Regeneron’s use of an alternate filler for Eylea HD as a positive development, with BMO Capital Markets noting that this could signal the end of manufacturing ...

Regeneron is planning to re-apply to the FDA with a new pre-filled syringe manufacturing filler in January 2026.

Q3 2025 Earnings Call Transcript October 28, 2025 Regeneron Pharmaceuticals, Inc. beats earnings expectations. Reported EPS ...

Guggenheim raised the firm’s price target on Regeneron (REGN) to $865 from $815 and keeps a Buy rating on the shares following Q3 performance that ...

Biotech company Regeneron (NASDAQ:REGN) reported Q3 CY2025 results exceeding the market’s revenue expectations, but sales were flat year on year at $3.75 billion. Its non-GAAP profit of $11.83 per ...